Qure NV (QURE) reports significant progress in Huntington's disease treatment but faces hurdles with FDA approval.

Columnist Allyx Formalejo reminds readers this National Epilepsy Awareness Month that some stories about epilepsy begin with ...

Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, ...

Medication has long been the cornerstone of treatment for people with epilepsy, but it doesn’t stop seizures for everyone and ...